The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hyperprogressive disease (HPD) during nivolumab (Nivo) or irinotecan (IRI) as salvage line in patients with metastatic gastric cancer (MGC).
 
Naotoshi Sugimoto
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Tomoyuki Otsuka
No Relationships to Disclose
 
Akiko Hasegawa
No Relationships to Disclose
 
Toshinari Yagi
No Relationships to Disclose
 
Toshihiro Kudo
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bayer Yakuhin
Research Funding - Bayer Yakuhin; Chugai Pharma; Lilly; Ono Pharmaceutical; Yakult Honsha
 
Koto Fujiishi
No Relationships to Disclose
 
Minako Nishio
No Relationships to Disclose
 
Sachiko Yamamoto
No Relationships to Disclose
 
Fumie Fujisawa
No Relationships to Disclose
 
Fumio Imamura
No Relationships to Disclose